RET C611Y Germline Variant in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Study
Authors:
- Anders Würgler HansenAHAnders Würgler Hansen
- Peter VestergaardPVPeter Vestergaard
- Morten Møller PoulsenMPMorten Møller Poulsen
- Åse Krogh RasmussenÅRÅse Krogh Rasmussen
- Ulla Feldt-RasmussenUFUlla Feldt-Rasmussen
- Mette MadsenMMMette Madsen
- Rune Weis NæraaRNRune Weis Næraa
- Dorte HansenDHDorte Hansen
- Katharina MainKMKatharina Main
- Henrik Baymler PedersenHPHenrik Baymler Pedersen
- Stefano Christian LonderoSLStefano Christian Londero
- Lars RolighedLRLars Rolighed
Open Access
Abstract
Background: Multiple endocrine neoplasia type 2A (MEN 2A) is a rare hereditary cancer syndrome caused by pathogenic variants in the rearranged during transfection (RET) gene and is characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), primary hyperparathyroidism (PHPT), cutaneous lichen amyloidosis (CLA), and Hirschsprung’s disease. Phenotypic data on the RET C611Y variant remain sparse. Consequently, we aimed to establish a clinical risk profile. Methods: We conducted a nationwide study of all cases (n = 128) born after 1 January 1930 and recognized as carrying the RET C611Y variant in Denmark before 1 April 2021. Results: The median follow-up after birth was 47 years (range, 3–92). Age-related penetrance at age 70 years for MTC was 98% (CI, 91–100), for PHEO 24% (CI, 16–37), and for PHPT 10% (CI, 5–20). None had CLA or Hirschsprung’s disease. The age-related progression of MTC was significant (p < 0.001). The mean age at T0N0M0 was 16 years (CI, 12–20), at T1-4N0M0 38 years (CI, 34–42), at TxN1M0 45 years (CI, 38–53) and at TxNxM1 49 years (CI, 36–61). At the last follow-up, 56% of thyroidectomized cases (n = 103) were biochemically cured. Overall survival at 70 years was 74% (CI, 59–84). Conclusions: RET C611Y is associated with a very high penetrance of MTC and a low penetrance of PHEO and PHPT. CLA and Hirschsprung’s disease almost never occur. MTC seems moderately aggressive, but large variability can be seen. Overall survival may be comparable to that of the general population.Keywords
Funding Information
- Odense University Hospital (142-A5632)
This publication has 38 references indexed in Scilit:
- Kidney malformations and Hirschsprung’s disease in carriers of cysteine mutations in exon 10 of the RET proto-oncogeneEndocrine, 2021
- Pheochromocytoma and ParagangliomaNew England Journal of Medicine, 2019
- Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective studyThe Lancet Diabetes & Endocrinology, 2019
- Genotype-specific progression of hereditary medullary thyroid cancerHuman Mutation, 2018
- The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary HyperparathyroidismJAMA Surgery, 2016
- Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensusOsteoporosis International, 2016
- Survival among people with Down syndrome: a nationwide population-based study in DenmarkGenetics in Medicine, 2013
- Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10Human Mutation, 2010
- The Relationship Between Specific RET Proto-oncogene Mutations and Disease Phenotype in Multiple Endocrine Neoplasia Type 2JAMA, 1996
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature, 1993